Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Binley

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Science (New York, N.Y.)|June 18, 2026
An HIV vaccine blueprintJames Binley
Current Opinion in HIV and AIDS|January 6, 2010
Specificities of broadly neutralizing anti-HIV-1 seraJames Binley
Biochemical and Biophysical Research Communications|July 21, 2006
Identification of a D-amino acid decapeptide HIV-1 entry inhibitorCésar Boggiano, Shibo Jiang, Hong Lu, et al.
Journal of Virology|May 23, 2008
Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccinationMichael Vaine, Shixia Wang, Emma T Crooks, et al.
Journal of Virology|December 15, 2004
The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundleLevon G Abrahamyan, Samvel R Mkrtchyan, James Binley, et al.
European Journal of Immunology|January 14, 2017
Type 1 diabetes pathogenesis is modulated by spontaneous autoimmune responses to endogenous retrovirus antigens in NOD miceRoman Bashratyan, Danielle Regn, M Jubayer Rahman, et al.
Journal of Virology|February 12, 2002
Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapyXia Jin, Murugappan Ramanathan, Shady Barsoum, et al.
Journal of Virology|September 13, 2003
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1Aran F Labrijn, Pascal Poignard, Aarti Raja, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Science (New York, N.Y.)|June 18, 2026
An HIV vaccine blueprintJames Binley
Current Opinion in HIV and AIDS|January 6, 2010
Specificities of broadly neutralizing anti-HIV-1 seraJames Binley
Biochemical and Biophysical Research Communications|July 21, 2006
Identification of a D-amino acid decapeptide HIV-1 entry inhibitorCésar Boggiano, Shibo Jiang, Hong Lu, et al.
Journal of Virology|May 23, 2008
Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccinationMichael Vaine, Shixia Wang, Emma T Crooks, et al.
Journal of Virology|December 15, 2004
The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundleLevon G Abrahamyan, Samvel R Mkrtchyan, James Binley, et al.
European Journal of Immunology|January 14, 2017
Type 1 diabetes pathogenesis is modulated by spontaneous autoimmune responses to endogenous retrovirus antigens in NOD miceRoman Bashratyan, Danielle Regn, M Jubayer Rahman, et al.
Journal of Virology|February 12, 2002
Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapyXia Jin, Murugappan Ramanathan, Shady Barsoum, et al.
Journal of Virology|September 13, 2003
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1Aran F Labrijn, Pascal Poignard, Aarti Raja, et al.
Pageof 1